Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference
Rhea-AI Summary
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the upcoming Citizens Life Sciences Conference in New York on May 7-8, 2025. CEO and Chairman Thomas Zindrick and CFO Matt Pulisic will engage in a fireside chat with Biotech Equity Research Managing Director Silvan Tuerkcan on May 8 at 1:30 p.m. ET. The discussion will focus on the company's clinical-stage programs and upcoming milestones.
The event will be accessible via webcast, with a replay available for 90 days on Genelux's IR page. The company will also conduct one-on-one meetings with institutional investors during the conference.
Positive
- None.
Negative
- None.
WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, CFO, will discuss clinical-stage programs and upcoming milestones in a fireside chat at the Citizens Life Sciences Conference taking place May 7-8, 2025, in New York.
The conversation with Biotech Equity Research Managing Director, Silvan Tuerkcan, PhD, is scheduled to begin at 1:30 p.m. ET on Thursday, May 8, 2025. A webcast link for the event will be available at https://wsw.com/webcast/jmp65/gnlx/1693890. An archived replay will be available for approximately 90 days following the event on the company’s IR page.
The Company will also attend one-on-one meetings during the conference. Institutional investors interested in arranging a meeting with Genelux management can register to attend the conference or contact genelux@allelecomms.com.
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and, VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & Platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a China-based, multi-center, open label Ph1b evaluating the efficacy and safety of Olvi-Vec & Platinum-doublet in recurrent small-cell lung cancer. The core of Genelux's discovery and development efforts revolves around its’ proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on Twitter @Genelux_Corp and on LinkedIn.
Investor and Media Contacts
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com
Source: Genelux Corporation
FAQ
When is Genelux (GNLX) presenting at the Citizens Life Sciences Conference 2025?
Who will represent Genelux (GNLX) at the Citizens Life Sciences Conference?
What topics will Genelux (GNLX) discuss at the Citizens Life Sciences Conference?
How can investors access Genelux's (GNLX) presentation at the Citizens Life Sciences Conference?
